SEC Form 4 · accession 0001553878-17-000055
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Akshay Vaishnaw
Officer — EVP, R&D
Period of report
Oct 30, 2017
Accepted (ET)
Nov 1, 2017 · 5:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 30, 2017 | M | 33,666 | $21.35 | A | 45,201 | D | |
| Common StockF2 | Oct 30, 2017 | S | 800 | $119.79 | D | 44,401 | D | |
| Common StockF3 | Oct 30, 2017 | S | 11,418 | $120.78 | D | 32,983 | D | |
| Common StockF4 | Oct 30, 2017 | S | 17,755 | $121.69 | D | 15,228 | D | |
| Common StockF5 | Oct 30, 2017 | S | 3,693 | $122.79 | D | 11,535 | D | |
| Common StockF6 | holding | — | — | — | 338 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $21.35 | Oct 30, 2017 | M | 33,666 | D | — | Dec 8, 2018 | Common Stock | 33,666 | 0 | D |
Explanation of responses
- F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2017.
- F2Sale prices ranged from $119.30 to $120.28.
- F3Sale prices ranged from $120.32 to $121.25.
- F4Sale prices ranged from $121.26 to $122.19.
- F5Sale prices ranged from $122.45 to $123.01.
- F6The reporting person owns 338 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F7The stock option vested as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.